In gynecology, the<unk> anikolaou test or<unk> anicolaou test (also called<unk>  smear,<unk> , cervical smear, or smear test) is a medical screening method, invented independently by Aurel Babeş and Georgios<unk> anikolaou, primarily designed to detect premalignant and malignant processes in the ectocervix. It may also detect infections and abnormalities in the endocervix and endometrium.
The endocervix may be partially sampled with the device used to obtain the ectocervical sample, but due to the anatomy of this area, consistent and reliable sampling cannot be guaranteed. As abnormal endocervical cells may be sampled, those examining them are taught to recognize them.
The endometrium is not directly sampled with the device used to sample the ectocervix. Cells may exfoliate onto the cervix and be collected from there, so as with endocervical cells, abnormal cells can be recognised if present but the<unk>  should not be used as a screening tool for endometrial malignancy.
The potentially pre-cancerous changes (called dysplasias or cervical or endocervical intraepithelial neoplasia) are usually caused by sexually transmitted human<unk> illomaviruses (HPVs).  The test aims to detect and prevent the progression of HPV-induced cervical cancer and other abnormalities in the female genital tract by sampling cells from the outer opening of the cervix (Latin for "neck") of the uterus and the endocervix. The sampling technique changed very little since its invention by Georgios<unk> anikolaou (1883–1962) to detect cyclic hormonal changes in vaginal cells in the early 20th century until the development of liquid based cell thinlayer technology.  The test remains an effective, widely used method for early detection of cervical cancer and pre-cancer.
The UK's call and recall system is among the best;[citation needed] estimates of its effectiveness vary widely but it may prevent about 700 deaths per year in the UK.
It is not a perfect test.  "A nurse performing 200 tests each year would prevent a death once in 38 years. During this time she or he would care for over 152 women with abnormal results, over 79 women would be referred for investigation, over 53 would have abnormal biopsy results, and over 17 would have persisting abnormalities for more than two years. At least one woman during the 38 years would die from cervical cancer despite being screened."
HPV vaccine may offer better prospects in the long term.
It is generally recommended that females who have had sex seek regular<unk>  smear testing. Guidelines on frequency vary, from annually to every five years. If results are abnormal, and depending on the nature of the abnormality, the test may need to be repeated in three to twelve months. If the abnormality requires closer scrutiny, the patient may be referred for detailed inspection of the cervix by colposcopy.  The patient may also be referred for HPV DNA testing, which can serve as an adjunct to<unk> ing.
About 5% to 7% of<unk>  smears produce abnormal results,[citation needed] such as dysplasia, possibly indicating a pre-cancerous condition. Although many low grade cervical dysplasias spontaneously regress without ever leading to cervical cancer, dysplasia can serve as an indication that increased vigilance is needed. Endocervical and endometrial abnormalities can also be detected, as can a number of infectious processes, including yeast and Trichomonas vaginalis. A small proportion of abnormalities are reported as of "uncertain significance".
Pap test
Pap smear
Pregnancy test
Breast examination
Vaginal cancer ultrasound
Breast self-examination
Endometrial cancer ultrasound
Human papillomavirus screening